TRAC: A Promising Cancer Treatment (G28755)

Target Name: TRAC

NCBI ID: G28755

TRAC

Other Name(s): IMD7 | TRA | T cell receptor alpha constant | TCRA | TRCA

TRAC: A Promising Cancer Treatment

TRAC (Tumor Receptor Antagonist) is a drug target (also known as an IMD7) that is involved in the treatment of various diseases, including cancer. TRAC works by targeting a specific protein called CD73, which is a protein that is expressed in many different types of cancer cells. By blocking the activity of CD73, TRAC can inhibit the formation of new blood vessels, which can be a source of tumor growth. This can lead to the death of cancer cells and a reduction in the size of existing tumors.

TRAC is currently being investigated as a potential drug target for various diseases, including cancer. In particular, TRAC is being tested as a potential cancer treatment by researchers at the University of California, San Francisco (UCSF).

One of the main benefits of TRAC is its ability to selectively target cancer cells, rather than healthy cells. This is because TRAC is designed to bind specifically to the protein CD73, which is only expressed in cancer cells. By blocking the activity of CD73, TRAC can selectively target cancer cells and minimize the potential for unintended side effects.

Another advantage of TRAC is its ability to inhibit the formation of new blood vessels. This can be a powerful tool in the treatment of cancer, because new blood vessels are often a source of tumor growth. By inhibiting the formation of new blood vessels, TRAC can slow down the growth of cancer cells and reduce their size.

In addition to its potential cancer-fighting properties, TRAC has also been shown to have potential benefits in treating other diseases. For example, TRAC has been shown to be effective in treating skin cancer, including melanoma. In addition, TRAC has been shown to be effective in treating autoimmune diseases, such as rheumatoid arthritis and lupus.

While TRAC is an promising drug target for cancer and other diseases, there are still some challenges that must be overcome before it can be widely used. For example, TRAC has not yet been fully tested in large clinical trials, so it is difficult to determine its safety and effectiveness. Additionally, the development of TRAC as a drug may be expensive and time-consuming, due to the need to conduct extensive preclinical and clinical testing.

Despite these challenges, however, TRAC is an promising drug target that has the potential to revolutionize the treatment of cancer and other diseases. As the research into TRAC continues, it is likely that new treatments will be developed that can effectively target TRAC and treat a wide range of diseases.

Protein Name: T Cell Receptor Alpha Constant

Functions: Constant region of T cell receptor (TR) alpha chain (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn, ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets